Dupixent Demonstrates Efficacy Treating Chronic Obstructive Pulmonary Disease, Asthma
Results from the Phase III BOREAS and NOTUS trials found that Dupixent reduced moderate-to-severe COPD exacerbations by 31% over 52 weeks.
October 24, 2026
Breaking News
Can an Office harassment lawyer negotiate a settlement? |
Why is Jack Bodenstein gaining attention? |
Which 100 Series Dash Mats offer the best fit and protection? |
Is oven repair Ottawa worth it for older electric and gas ovens? |
How often should organizations conduct a cloud penetration test? |
